Strontium ranelate, a therapeutic for osteoporosis, was thought to have a dual mode of action, simultaneously stimulating bone formation and reducing resorption. A recent study casts doubt on this ...

Sept. 26, 2005 (Nashville) -- Strontium ranelate is one of the first drugs to have a dual action that both decreases bone resorption and increases bone formation, according to a study presented here ...

Oct. 29, 2002 (New Orleans) - Strontium ranelate, an investigational drug with a novel mechanism of action against osteoporosis, appears to reduce the incidence of vertebral fractures in ...

As a weapon against osteoporosis, the drug’s beginnings were inauspicious -- it was shelved for almost 50 years, and its main component is a mineral widely regarded as nonessential. But the compound ...

SAN DIEGO, CA—Using a new definition of radiological progression, patients with osteoarthritis of the knee treated with strontium ranelate had a significant reduction in such progression, “suggesting ...

Strontium ranelate—which is approved for the treatment of postmenopausal osteoporosis—has substantial structure-modifying activity and slows the progression of knee osteoarthritis (OA), according to ...

An experimental drug containing strontium makes bones denser and decreases the risk of fractures, a study of elderly women finds. The results add the drug, called strontium ranelate, to a wave of new ...

We recently reported on a study that found encouraging results for patients taking a nutritional supplement called strontium ranelate for knee problems. The supplement is also used by women with ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. An error has occurred. Please try again ...

Medicines regulators are considering whether the osteoporosis drug strontium ranelate should be withdrawn, after being advised the drug should no longer be prescribed for the condition due to concerns ...